A new study from UCLA Health suggests COVID-19 vaccines may protect patients from severe kidney damage. The study found ...

Women who use an oral contraceptive might want to consider using a back-up method after starting a weight loss drug.

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

A study from Mass General Brigham and Harvard Medical School raises questions about a new class of weight loss drugs — and ...

Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...

It’s the hot-shot fix that took Hollywood — and now high school — by storm. Ozempic and other so-called “miracle” weight-loss ...

Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...